Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Defined term · Pharmacology

Area postrema

A circumventricular structure lacking a complete blood–brain barrier, accessible to circulating peptides and central to both the satiety and the nausea effects of this compound class.

Document identifier
CEI-GT-125
Series
Defined term
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Area postrema

§1.2Category

Pharmacology — Terms describing how a compound acts and how the body handles it.

§1.3Related terms

  • GLP-1 receptor agonist — A compound activating the glucagon-like peptide-1 receptor, a class B G protein-coupled receptor signalling principally through Gαs. Effects include glucose-dependent…
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.